BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 ...
(PR-inside.com) LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV) Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and overcome resistance BI-1206 boosts αPD-1 antibody activity by protecting effector CD8+ T cells from mac…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


